Whither the pharma Grand Prix? Questions abound in run-up to Cannes health fest
The Cannes Lions are rapidly approaching, but along with anticipation comes much uncertainty among key players in healthcare marketing. A number of major changes intended to make the confab more accessible were introduced last year, but the question remains: Will U.S. pharma be a major presence at the festival in June, or will it largely remain on the sidelines as the past years have seemed to suggest? And, given other rule changes designed to separate regulated from non-regulated work, are jurors any more likely to bestow a pharma Grand Prix?